barrett's%20esophagus
BARRETT'S ESOPHAGUS
Barrett's esophagus is defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology.
It is considered a premalignant metaplastic condition that usually involves the distal esophagus.
It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process.

Barrett's%20esophagus Signs and Symptoms

Introduction

  • Barrett’s esophagus is considered a premalignant metaplastic condition that usually involves the distal esophagus
  • It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process
  • The incidence of progressing to adenocarcinoma is approximately 0.27-0.59% of Barrett’s esophagus patients per year
  • Barrett’s esophagus is diagnosed by endoscopy and histological examination

Definition

  • Defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology
    • Intestinal metaplasia is not required for diagnosis, though risk of progression to carcinoma is higher in its presence

Risk Factors

  • White or Hispanic race
  • Male
  • Advancing age (>50 years, reaching a plateau in the 60’s) - reported as a significant risk factor in various Asian studies
  • Hiatal hernia
  • Smoking
  • Central obesity (intra-abdominal body fat distribution)
  • Alcohol (as shown in an Asian study)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.